Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs) tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations

Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs) : tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations

Copyright © 2020. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 214(2020) vom: 15. Mai, Seite 108395
1. Verfasser: Gremese, Elisa (VerfasserIn)
Weitere Verfasser: Alivernini, Stefano, Ferraccioli, Edoardo Sean, Ferraccioli, Gianfranco
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Review CPI Immuno-rheumatologic related adverse events(irAEs) Loss of tolerance Tolerance Antineoplastic Agents, Immunological B7-H1 Antigen CD274 protein, human CTLA-4 Antigen mehr... CTLA4 protein, human PDCD1 protein, human Programmed Cell Death 1 Receptor Tumor Suppressor Proteins Abatacept 7D0YB67S97
Beschreibung
Zusammenfassung:Copyright © 2020. Published by Elsevier Inc.
Immune related adverse events (irAEs) have been observed with all checkpoint inhibitors and are very frequent. The evidences coming from experimental models of congenital or acquired deficiency of CTLA-4 or from PD-1 knock-out mice, provided all the informations to interpret the organ or systemic manifestations (endocrine, or systemic autoimmune chronic inflammatory diseases-ACIDs) observed in trials as well as in registries of cohorts treated with anti-CTLA-4 or anti-PD-1/PD-L1 inhibitors, or combination therapies. Finally the concern raised by cancers occurring in patients with autoimmune diseases (Systemic Lupus Erythematosus, Myositis, Rheumatoid Arthritis, Psoriatic Arthritis, Vasculitis, Scleroderma, Polymyalgia Rheumatica and others) and how to deal with immunotherapy was discussed. The biological knowledges acquired with the immunotherapy trials, have paved to way to better treat autoimmune diseases in patients developing cancer during the autoimmune illness. Immunotherapy without Autoimmunity is the unmet need within our reach in the future
Beschreibung:Date Completed 23.10.2020
Date Revised 23.10.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2020.108395